10-K: Harmony Biosciences Holdings Reports Strong 2024 Results, Navigates Regulatory Hurdles

Harmony Biosciences Holdings, Inc. announces its 2024 financial results, highlighting growth in WAKIX sales while addressing regulatory challenges and pipeline expansion.

Summary

• Harmony Biosciences Holdings, Inc. released its 10-K filing for the year ended December 31, 2024, showcasing its focus on neuroscience and addressing unmet needs in neurological diseases.
• The company's lead product, WAKIX, experienced continued growth, with net product revenue reaching $714.7 million in 2024.
• Harmony submitted a supplemental New Drug Application (sNDA) for pitolisant in Idiopathic Hypersomnia (IH) but received a Refusal to File letter from the FDA in February 2025.
• The company is advancing clinical programs for pitolisant in Prader-Willi syndrome (PWS) and myotonic dystrophy type 1 (DM1).
• Harmony acquired Zynerba Pharmaceuticals, Inc. in October 2023, adding ZYN-002 for neurobehavioral conditions to its pipeline, with Phase 3 trials underway for Fragile X syndrome (FXS) and planned for 22q deletion syndrome (22q) in 2025.
• In April 2024, Harmony expanded into orexin science through a sublicense agreement with Bioprojet for an orexin 2 receptor agonist (BP1.15205).
• Harmony acquired Epygenix Therapeutics, Inc., adding EPX-100 and EPX-200 to its rare epilepsy franchise, with EPX-100 in Phase 3 trials for Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS).
• The company faces competition from other pharmaceutical companies, including Jazz Pharmaceuticals, Axsome Therapeutics, and Avadel Pharmaceuticals.
• Harmony relies on third-party manufacturers for WAKIX and its product candidates.
• The company is subject to various healthcare laws and regulations, including the Anti-Kickback Statute and the False Claims Act.
• Harmony's corporate headquarters are located in Plymouth Meeting, Pennsylvania, and it had 268 full-time employees as of December 31, 2024.
• The company's Board of Directors approved a share repurchase program in October 2023, authorizing repurchases of up to $200 million of common stock.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While the company shows strong revenue growth and pipeline expansion, regulatory setbacks and competition temper the overall outlook.

Positives

• WAKIX net product revenue increased by $132.7 million, or 22.8%, for the year ended December 31, 2024, compared to the same period in 2023.
• The company has secured formulary access for more than 80% of all insured lives (Commercial, Medicare and Medicaid) in the United States.
• The FDA granted Orphan Drug designation to pitolisant for the treatment of PWS in February 2024.
• The company has a robust supply of raw material inventory and an 18 month supply of finished goods inventory to ensure product availability.
• The company has a strong cash position with $576.1 million in cash, cash equivalents, and investments as of December 31, 2024.

Negatives

• The FDA issued a Refusal to File letter for pitolisant in IH in February 2025.
• The FDA did not approve Harmony's sNDA seeking to expand the WAKIX label for the treatment of pediatric patients with cataplexy in June 2024.
• The company relies on third-party manufacturers for WAKIX and its product candidates, including certain sole-source suppliers and manufacturers.
• The company faces competition from other pharmaceutical companies, including Jazz Pharmaceuticals, Axsome Therapeutics, and Avadel Pharmaceuticals.
• The company is subject to ongoing regulatory obligations and continued regulatory review with respect to WAKIX, which will result in significant additional expense.

Risks

• The company is substantially dependent on the commercial success of WAKIX.
• The regulatory approval process of the FDA is costly, lengthy, and inherently unpredictable.
• If the company fails to obtain and sustain an adequate level of coverage and reimbursement for WAKIX and other product candidates by third-party payors, sales would be adversely affected.
• Raising additional funds by issuing securities may cause dilution to existing shareholders, raising additional funds through debt financings may involve restrictive covenants, and raising funds through lending and licensing arrangements may restrict operations or require relinquishing proprietary rights.
• The company may be subject to fines, penalties, or injunctions if it is determined to have promoted or be promoting the use of pitolisant for unapproved or off-label uses.
• If the company is unable to obtain and maintain patent protection for its technology and products, or if the scope of the patent protection obtained is not sufficiently broad, it may not be able to compete effectively in its markets.
• The company's directors, officers, and principal stockholders beneficially own a significant percentage of its stock and are able to exert significant control over matters subject to stockholder approval.
• Future sales of the company's common stock in the public market, including sales by its directors, officers, or significant shareholders, could cause its share price to fall.
• Public health pandemics, such as the COVID-19 pandemic, may result in disruptions to the company's commercialization, clinical trials, manufacturing, and other business operations.

Future Outlook

Harmony plans to resubmit an sNDA for WAKIX for the treatment of pediatric patients with cataplexy in the second quarter of 2025. The company also plans to file an investigational medicinal product dossier (IMPD) with the European Medicines Agency (EMA) in mid-2025 and begin first-in-human studies in the second half of 2025 for BP1.15205. Topline data from Harmony's ZYN-002 Phase 3 study is anticipated in the third quarter of 2025. Harmony plans to initiate a Phase 3 registrational study in 22q deletion syndrome in 2025.

Industry Context

The U.S. narcolepsy market had an approximate net sales value of $2.9 billion in 2023 and is expected to continue to grow. The company faces competition from other pharmaceutical companies, including Jazz Pharmaceuticals, Axsome Therapeutics, and Avadel Pharmaceuticals.

Comparison to Industry Standards

• WAKIX competes with currently FDA-approved products for the treatment of EDS or cataplexy in adult patients with narcolepsy and EDS in children six years and older with narcolepsy, all of which are controlled substances.
• Jazz Pharmaceuticals Xyrem (sodium oxybate) is an FDA-approved product for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy.
• Axsomes Sunosi (solriamfetol) was approved by the FDA in March 2019 and launched in July 2019.
• Avadel Pharmaceuticals launched a once nightly formulation version of sodium oxybate in June 2023.
• Other potential future competitive products are currently in development, including Axsome Therapeutics AXS-12 (reboxetine) product candidate, Suven Life Sciences SUVN-G3031 H3 inverse agonist product candidate, NLS Pharmaceutics mazindol ER product candidate and orexin 2 receptor agonist product candidates from Takeda, Jazz Pharmaceuticals/Sumitomo Pharma, Centessa and Alkermes among others.

Legal Proceedings

• The company is involved in ANDA litigation with Lupin, Novugen, Novitium, Zenara, AET, and MSN regarding generic versions of WAKIX.
• On October 31, 2024, the Company reached an agreement with Novugen Pharma to resolve the dispute over Novugens ANDA for a generic pitolisant hydrochloride product.

Related Party Transactions

• The company is party to a right of use agreement with Paragon Biosciences, LLC, an entity that shares common ownership with the company.

Stakeholder Impact

• The company's performance impacts shareholders, employees, customers, suppliers, and creditors.
• The company collaborates with patient advocacy organizations to understand the needs of patients living with rare, neurological disorders, and are committed to addressing those needs.

Next Steps

• Resubmit an sNDA for WAKIX for the treatment of pediatric patients with cataplexy in the second quarter of 2025.
• File an investigational medicinal product dossier (IMPD) with the European Medicines Agency (EMA) in mid-2025 and begin first-in-human studies in the second half of 2025 for BP1.15205.
• Release topline data from the ZYN-002 Phase 3 study in the third quarter of 2025.
• Initiate a Phase 3 registrational study in 22q deletion syndrome in 2025.
• Continue Phase 3 registrational clinical trial for EPX-100 in DS and LGS.

Key Dates